Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation

ACS Nano

Volumn 8, Issue 5, 2014, Pages 4996-5009

  Guo, Shutao ^a   Lin, C Michael ^a   Xu, Zhenghong ^a   Miao, Lei ^a   Wang, Yuhua ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

antiangiogenesis; cisplatin; combination therapy; PLGA; rapamycin; synergistic effect; Tumor microenvironment

Indexed keywords

CELL DEATH; COPOLYMERS; DERMATOLOGY; MODULATION; ONCOLOGY; TUMORS;

ANTIANGIOGENESIS; CIS-PLATIN; COMBINATION THERAPY; PLGA; RAPAMYCIN; SYNERGISTIC EFFECT; TUMOR MICROENVIRONMENT;

PLATINUM COMPOUNDS;

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CISPLATIN; DOPA; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RAPAMYCIN; SOLVENT;

ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE COURSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MELANOMA; METASTASIS; MOUSE; NANOTECHNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUNEL ASSAY;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; DRUG CARRIERS; HUMANS; IN SITU NICK-END LABELING; LACTIC ACID; MELANOMA; MICE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; POLYGLYCOLIC ACID; SIROLIMUS; SKIN NEOPLASMS; SOLVENTS; TUMOR MICROENVIRONMENT;

EID: 84901684242     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn5010815     Document Type: Article

References (56)

1. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Karydas, A. G.; Ithakissios, D. S. Plga-Mpeg Nanoparticles of Cisplatin: In Vitro Nanoparticle Degradation, in Vitro Drug Release and in Vivo Drug Residence in Blood Properties J. Controlled Release 2002, 79, 123-135
2. Heldin, C.-H.; Rubin, K.; Pietras, K.; Östman, A. High Interstitial Fluid Pressure-An Obstacle in Cancer Therapy Nat. Rev. Cancer 2004, 4, 806-813
3. Kalluri, R.; Zeisberg, M. Fibroblasts in Cancer Nat. Rev. Cancer 2006, 6, 392-401
4. Garber, K. Stromal Depletion Goes on Trial in Pancreatic Cancer J. Natl. Cancer Inst. 2010, 102, 448-450
5. Murakami, M.; Ernsting, M. J.; Undzys, E.; Holwell, N.; Foltz, W. D.; Li, S. D. Docetaxel Conjugate Nanoparticles That Target Alpha-Smooth Muscle Actin-Expressing Stromal Cells Suppress Breast Cancer Metastasis Cancer Res. 2013, 73, 4862-4871
6. Diop-Frimpong, B.; Chauhan, V. P.; Krane, S.; Boucher, Y.; Jain, R. K. Losartan Inhibits Collagen I Synthesis and Improves the Distribution and Efficacy of Nanotherapeutics in Tumors Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 2909-2914
7. Loeffler, M.; Kruger, J. A.; Niethammer, A. G.; Reisfeld, R. A. Targeting Tumor-Associated Fibroblasts Improves Cancer Chemotherapy by Increasing Intratumoral Drug Uptake J. Clin. Invest. 2006, 116, 1955-1962
8. Kano, M. R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M. Improvement of Cancer-Targeting Therapy, Using Nanocarriers for Intractable Solid Tumors by Inhibition of Tgf-B Signaling Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3460-3465
9. Beatty, G. L.; Chiorean, E. G.; Fishman, M. P.; Saboury, B.; Teitelbaum, U. R.; Sun, W.; Huhn, R. D.; Song, W.; Li, D.; Sharp, L. L. Cd40 Agonists Alter Tumor Stroma and Show Efficacy against Pancreatic Carcinoma in Mice and Humans Science 2011, 331, 1612-1616
10. Smalley, K. S.; Haass, N. K.; Brafford, P. A.; Lioni, M.; Flaherty, K. T.; Herlyn, M. Multiple Signaling Pathways Must Be Targeted to Overcome Drug Resistance in Cell Lines Derived from Melanoma Metastases Mol. Cancer Ther. 2006, 5, 1136-1144
11. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Li, Y.; Chen, Y. Z. Mechanisms of Drug Combinations: Interaction and Network Perspectives Nat. Rev. Drug Discovery 2009, 8, 111-128
12. Lasithiotakis, K. G.; Sinnberg, T. W.; Schittek, B.; Flaherty, K. T.; Kulms, D.; Maczey, E.; Garbe, C.; Meier, F. E. Combined Inhibition of Mapk and Mtor Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells J. Invest. Dermatol. 2008, 128, 2013-2023
13. Chou, T.-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev. 2006, 58, 621-681
14. Chou, T.-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method Cancer Res. 2010, 70, 440-446
15. Schnell, C. R.; Stauffer, F.; Allegrini, P. R.; O'Reilly, T.; McSheehy, P. M.; Dartois, C.; Stumm, M.; Cozens, R.; Littlewood-Evans, A.; Garcia-Echeverria, C. Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor Nvp-Bez235 on the Tumor Vasculature: Implications for Clinical Imaging Cancer Res. 2008, 68, 6598-6607
16. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M. Rapamycin Inhibits Primary and Metastatic Tumor Growth by Antiangiogenesis: Involvement of Vascular Endothelial Growth Factor Nat. Med. 2002, 8, 128-135
17. Zhang, Q.; Bindokas, V.; Shen, J.; Fan, H.; Hoffman, R. M.; Xing, H. R. Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents Mol. Cancer Ther. 2011, 10, 1173-1184
18. Haddadi, A.; Elamanchili, P.; Lavasanifar, A.; Das, S.; Shapiro, J.; Samuel, J. Delivery of Rapamycin by Plga Nanoparticles Enhances Its Suppressive Activity on Dendritic Cells J. Biomed. Mater. Res., Part A 2008, 84, 885-898
19. Lin, P. Y.; Fosmire, S. P.; Park, S. H.; Park, J. Y.; Baksh, S.; Modiano, J. F.; Weiss, R. H. Attenuation of Pten Increases P21 Stability and Cytosolic Localization in Kidney Cancer Cells: A Potential Mechanism of Apoptosis Resistance Mol. Cancer 2007, 6, 16
20. Mungamuri, S. K.; Yang, X.; Thor, A. D.; Somasundaram, K. Survival Signaling by Notch1: Mammalian Target of Rapamycin (Mtor)-Dependent Inhibition of P53 Cancer Res. 2006, 66, 4715-4724
21. Tanaka, K.; Sasayama, T.; Mizukawa, K.; Kawamura, A.; Kondoh, T.; Hosoda, K.; Fujiwara, T.; Kohmura, E. Specific Mtor Inhibitor Rapamycin Enhances Cytotoxicity Induced by Alkylating Agent 1-(4-Amino-2-Methyl-5-Pyrimidinyl) Methyl-3-(2-Chloroethyl)-3-Nitrosourea (Acnu) in Human U251 Malignant Glioma Cells J. Neurooncol. 2007, 84, 233-244
22. Zhang, Y.; Kim, W. Y.; Huang, L. Systemic Delivery of Gemcitabine Triphosphate Via Lcp Nanoparticles for Nsclc and Pancreatic Cancer Therapy Biomaterials 2013, 34, 3447-3458
23. Li, J.; Yang, Y.; Huang, L. Calcium Phosphate Nanoparticles with an Asymmetric Lipid Bilayer Coating for Sirna Delivery to the Tumor J. Controlled Release 2012, 158, 108-114
24. Xu, Z.; Ramishetti, S.; Tseng, Y. C.; Guo, S.; Wang, Y.; Huang, L. Multifunctional Nanoparticles Co-Delivering Trp2 Peptide and Cpg Adjuvant Induce Potent Cytotoxic T-Lymphocyte Response against Melanoma and Its Lung Metastasis J. Controlled Release 2013, 172, 259-265
25. Guo, S.; Wang, Y.; Miao, L.; Xu, Z.; Lin, C. M.; Zhang, Y.; Huang, L. Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy ACS Nano 2013, 7, 9896-9904
26. Guo, S.; Miao, L.; Wang, Y.; Huang, L. Unmodified Drug Used as a Material to Construct Nanoparticles: Delivery of Cisplatin for Enhanced Anti-Cancer Therapy J. Controlled Release 2014, 174, 137-142
27. Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B. D.; Pink, J.; Boothman, D. A.; Gao, J. Crgd-Functionalized Polymer Micelles for Targeted Doxorubicin Delivery Angew. Chem. 2004, 116, 6483-6487
28. Kim, J.; Lee, J. E.; Lee, S. H.; Yu, J. H.; Lee, J. H.; Park, T. G.; Hyeon, T. Designed Fabrication of a Multifunctional Polymer Nanomedical Platform for Simultaneous Cancer-Targeted Imaging and Magnetically Guided Drug Delivery Adv. Mater. 2008, 20, 478-483
29. Chang, J.-Y.; Yang, C.-H.; Huang, K.-S. Microfluidic Assisted Preparation of Cdse/Zns Nanocrystals Encapsulated into Poly (Dl-Lactide-Co-Glycolide) Microcapsules Nanotechnology 2007, 18, 305305
30. Nehilla, B. J.; Allen, P. G.; Desai, T. A. Surfactant-Free, Drug-Quantum-Dot Coloaded Poly(Lactide-Co-Glycolide) Nanoparticles: Towards Multifunctional Nanoparticles ACS Nano 2008, 2, 538-544
31. Vivero-Escoto, J. L.; Taylor-Pashow, K. M.; Huxford, R. C.; Della Rocca, J.; Okoruwa, C.; An, H.; Lin, W.; Lin, W. Multifunctional Mesoporous Silica Nanospheres with Cleavable Gd (Iii) Chelates as Mri Contrast Agents: Synthesis, Characterization, Target-Specificity, and Renal Clearance Small 2011, 7, 3519-3528
32. Nakagawa, O.; Ming, X.; Huang, L.; Juliano, R. L. Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands J. Am. Chem. Soc. 2010, 132, 8848-8849
33. Banerjee, R.; Tyagi, P.; Li, S.; Huang, L. Anisamide-Targeted Stealth Liposomes: A Potent Carrier for Targeting Doxorubicin to Human Prostate Cancer Cells Int. J. Cancer 2004, 112, 693-700
34. Gaedeke, J.; Fels, L. M.; Bokemeyer, C.; Mengs, U.; Stolte, H.; Lentzen, H. Cisplatin Nephrotoxicity and Protection by Silibinin Nephrol. Dial. Transpl. 1996, 11, 55-62
35. Spitz, D. R.; Phillips, J. W.; Adams, D. T.; Sherman, C. M.; Deen, D. F.; Li, G. C. Cellular Resistance to Oxidative Stress Is Accompanied by Resistance to Cisplatin: The Significance of Increased Catalase Activity and Total Glutathione in Hydrogen Peroxide-Resistant Fibroblasts J. Cell. Physiol. 1993, 156, 72-79
36. Gregg, R. W.; Molepo, J. M.; Monpetit, V. J.; Mikael, N. Z.; Redmond, D.; Gadia, M.; Stewart, D. J. Cisplatin Neurotoxicity: The Relationship between Dosage, Time, and Platinum Concentration in Neurologic Tissues, and Morphologic Evidence of Toxicity J. Clin. Oncol. 1992, 10, 795-803
37. Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and Practical Approaches for Prediction of Drug-Polymer Miscibility and Solubility Pharm. Res. 2006, 23, 2417-2426
38. Kim, S.; Shi, Y.; Kim, J. Y.; Park, K.; Cheng, J.-X. Overcoming the Barriers in Micellar Drug Delivery: Loading Efficiency, in Vivo Stability, and Micelle-Cell Interaction Expert Opin. Drug Delivery 2010, 7, 49-62
39. Lu, Y.; Park, K. Polymeric Micelles and Alternative Nanonized Delivery Vehicles for Poorly Soluble Drugs Int. J. Pharm. 2013, 453, 198-214
40. Ling, Y.; Wei, K.; Luo, Y.; Gao, X.; Zhong, S. Dual Docetaxel/ Superparamagnetic Iron Oxide Loaded Nanoparticles for Both Targeting Magnetic Resonance Imaging and Cancer Therapy Biomaterials 2011, 32, 7139-7150
41. Dilnawaz, F.; Singh, A.; Mohanty, C.; Sahoo, S. K. Dual Drug Loaded Superparamagnetic Iron Oxide Nanoparticles for Targeted Cancer Therapy Biomaterials 2010, 31, 3694-3706
42. Oliveira, R. R.; Ferreira, F. S.; Cintra, E. R.; Branquinho, L. C.; Bakuzis, A. F.; Lima, E. M. Magnetic Nanoparticles and Rapamycin Encapsulated into Polymeric Nanocarriers J. Biomed. Nanotechnol. 2012, 8, 193-201
43. Zhang, J.; Miao, L.; Guo, S.; Zhang, Y.; Zhang, L.; Satterlee, A.; Kim, W. Y.; Huang, L. Synergistic Anti-Tumor Effects of Combined Gemcitabine and Cisplatin Nanoparticles in a Stroma-Rich Bladder Carcinoma Model J. Controlled Release 2014, 182, 90-96
44. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-Functionalized Peg-Plga Nanoparticles for Enhanced Anti-Glioma Drug Delivery Biomaterials 2011, 32, 8010-8020
45. Provenzano, P. P.; Cuevas, C.; Chang, A. E.; Goel, V. K.; Von Hoff, D. D.; Hingorani, S. R. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma Cancer Cell 2012, 21, 418-429
46. Erez, N.; Truitt, M.; Olson, P.; Arron, S. T.; Hanahan, D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an Nf-Kappab-Dependent Manner Cancer Cell 2010, 17, 135-147
47. Carmeliet, P.; Jain, R. K. Angiogenesis in Cancer and Other Diseases Nature 2000, 407, 249-257
48. Jain, R. K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science 2005, 307, 58-62
49. Fokas, E.; Im, J. H.; Hill, S.; Yameen, S.; Stratford, M.; Beech, J.; Hackl, W.; Maira, S. M.; Bernhard, E. J.; McKenna, W. G. Dual Inhibition of the Pi3k/Mtor Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature Cancer Res. 2012, 72, 239-248
50. Neuzillet, C.; Tijeras-Raballand, A.; Cros, J.; Faivre, S.; Hammel, P.; Raymond, E. Stromal Expression of Sparc in Pancreatic Adenocarcinoma Cancer Metastasis Rev. 2013, 10.1007/s10555-10013-19439-10553
51. Von Hoff, D. D.; Ramanathan, R. K.; Borad, M. J.; Laheru, D. A.; Smith, L. S.; Wood, T. E.; Korn, R. L.; Desai, N.; Trieu, V.; Iglesias, J. L. Gemcitabine Plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/Ii Trial J. Clin. Oncol. 2011, 29, 4548-4554
52. Dormond-Meuwly, A.; Dufour, M.; Demartines, N.; Dormond, O. Mtor Inhibition and the Tumor Vasculature Curr. Angiog. 2012, 1, 11-19
53. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674
54. Hainaut, P.; Plymoth, A. Targeting the Hallmarks of Cancer: Towards a Rational Approach to Next-Generation Cancer Therapy Curr. Opin. Oncol. 2013, 25, 50-51
55. Kano, M. R.; Bae, Y.; Iwata, C.; Morishita, Y.; Yashiro, M.; Oka, M.; Fujii, T.; Komuro, A.; Kiyono, K.; Kaminishi, M. Improvement of Cancer-Targeting Therapy, Using Nanocarriers for Intractable Solid Tumors by Inhibition of Tgf-Beta Signaling Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3460-3465
56. Meng, H.; Zhao, Y.; Dong, J.; Xue, M.; Lin, Y. S.; Ji, Z.; Mai, W. X.; Zhang, H.; Chang, C. H.; Brinker, C. J. Two-Wave Nanotherapy to Target the Stroma and Optimize Gemcitabine Delivery to a Human Pancreatic Cancer Model in Mice ACS Nano 2013, 7, 10048-10065